Search

Displaying results 6041 - 6050 of 10000 in total
  1. Drug

    Agrostis gigantea top

    go.drugbank.com/drugs/DB14757
    ApprovedWithdrawn

    Agrostis gigantea top is the flowering part of the Agrostis gigantea plant. Agrostis gigantea top is mainly used in allergenic testing.

  2. Drug

    Nicotinamide riboside

    go.drugbank.com/drugs/DB14933
    ApprovedInvestigationalWithdrawn

    Nicotinamide riboside is under investigation in clinical trial NCT03432871 (Nicotinamide Riboside and Mitochondrial Biogenesis).

  3. Drug

    Benzquinamide

    go.drugbank.com/drugs/DB00767
    ApprovedWithdrawn

    Benzquinamide is a discontinued antiemetic compound with antihistaminic, mild anticholinergic, and sedative properties. … The mechanism of action is not known, but presumably benzquinamide works via antagonism of muscarinic acetycholine receptors and histamine H1 receptors.

  4. Drug

    rhGAD65

    go.drugbank.com/drugs/DB04963
    Investigational

    rhGAD65 (recombinant human glutamic acid decarboxylase) is a vaccine being developed to treat insulin dependent type 1 diabetes.

  5. Drug

    Farletuzumab

    go.drugbank.com/drugs/DB05595
    Investigational

    Farletuzumab (MORAb-003) is a fully humanized monoclonal antibody against the folate receptor alpha, for the potential treatment of epithelial ovarian cancer.

  6. Drug

    Flavin adenine dinucleotide

    go.drugbank.com/drugs/DB03147
    Approved

    (Lehninger, Principles of Biochemistry, 1982, p972) Flavin adenine dinucleotide is approved for use in Japan under the trade name Adeflavin as an ophthalmic treatment for vitamin B2 deficiency.

  7. Drug

    Bithionol

    go.drugbank.com/drugs/DB04813
    ApprovedWithdrawn

    Bithionol, formerly marketed as an active ingredient in various topical drug products, was shown to be a potent photosensitizer with the potential to cause serious skin disorders. … Approvals of the NDA's for bithionol drug products were withdrawn on October 24, 1967 (see the Federal Register of October 31, 1967 (32 FR 15046)).

  8. Drug

    Lexatumumab

    go.drugbank.com/drugs/DB06599
    Investigational

    Lexatumumab is a fully humanized, high-affinity immunoglobulin G(1 lambda) monoclonal antibody (mAb).

  9. Drug

    KB001

    go.drugbank.com/drugs/DB05222
    Investigational

    KB001 is a Humaneered™ PEGylated monoclonal antibody fragment for the treatment of life-threatening Pseudomonas aeruginosa infections, a common problem of cystic fibrosis and mechanically ventilated

  10. Drug

    OP-145

    go.drugbank.com/drugs/DB05672
    Experimental

    OP-145 is a synthetic antimicrobial peptide developed from human cathelicidin LL-37.